Shattuck Labs Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.1
- Today's High:
- $2.22
- Open Price:
- $2.22
- 52W Low:
- $1.85
- 52W High:
- $4.765
- Prev. Close:
- $2.19
- Volume:
- 16568
Company Statistics
- Market Cap.:
- $93.01 million
- Book Value:
- 3.26
- Revenue TTM:
- $859000
- Operating Margin TTM:
- -11165.66%
- Gross Profit TTM:
- $-82247000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.49%
- Return on Equity TTM:
- -51.04%
Company Profile
Shattuck Labs Inc had its IPO on 2020-10-09 under the ticker symbol STTK.
The company operates in the Healthcare sector and Biotechnology industry. Shattuck Labs Inc has a staff strength of 105 employees.
Stock update
Shares of Shattuck Labs Inc opened at $2.22 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.1 - $2.22, and closed at $2.1.
This is a -4.11% slip from the previous day's closing price.
A total volume of 16,568 shares were traded at the close of the day’s session.
In the last one week, shares of Shattuck Labs Inc have slipped by -6.67%.
Shattuck Labs Inc's Key Ratios
Shattuck Labs Inc has a market cap of $93.01 million, indicating a price to book ratio of 0.5314 and a price to sales ratio of 3.5349.
In the last 12-months Shattuck Labs Inc’s revenue was $859000 with a gross profit of $-82247000 and an EBITDA of $-91933000. The EBITDA ratio measures Shattuck Labs Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Shattuck Labs Inc’s operating margin was -11165.66% while its return on assets stood at -29.49% with a return of equity of -51.04%.
In Q2, Shattuck Labs Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 300%.
Shattuck Labs Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Shattuck Labs Inc’s profitability.
Shattuck Labs Inc stock is trading at a EV to sales ratio of 68.9414 and a EV to EBITDA ratio of 1.1448. Its price to sales ratio in the trailing 12-months stood at 3.5349.
Shattuck Labs Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $155.27 million
- Total Liabilities
- $12.99 million
- Operating Cash Flow
- $24.43 million
- Capital Expenditure
- $296000
- Dividend Payout Ratio
- 0%
Shattuck Labs Inc ended 2024 with $155.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $155.27 million while shareholder equity stood at $138.46 million.
Shattuck Labs Inc ended 2024 with $0 in deferred long-term liabilities, $12.99 million in other current liabilities, 5000.00 in common stock, $-261082000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $71.89 million and cash and short-term investments were $117.17 million. The company’s total short-term debt was $747,000 while long-term debt stood at $0.
Shattuck Labs Inc’s total current assets stands at $136.45 million while long-term investments were $0 and short-term investments were $45.28 million. Its net receivables were $2.81 million compared to accounts payable of $2.01 million and inventory worth $0.
In 2024, Shattuck Labs Inc's operating cash flow was $24.43 million while its capital expenditure stood at $296000.
Comparatively, Shattuck Labs Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.1
- 52-Week High
- $4.765
- 52-Week Low
- $1.85
- Analyst Target Price
- $16
Shattuck Labs Inc stock is currently trading at $2.1 per share. It touched a 52-week high of $4.765 and a 52-week low of $4.765. Analysts tracking the stock have a 12-month average target price of $16.
Its 50-day moving average was $2.43 and 200-day moving average was $2.91 The short ratio stood at 18.3 indicating a short percent outstanding of 0%.
Around 1937.3% of the company’s stock are held by insiders while 4787.6% are held by institutions.
Frequently Asked Questions About Shattuck Labs Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.